We are seeking adults with Down Syndrome without any signs or symptoms of dementia to gather information needed for the development of future clinical trials on Alzheimer’s Disease in the Down Syndrome population. Individuals enrolled will undergo neuropsychological testing, imaging studies, and have blood and urine samples collected for clinical and genetic studies.
Principal Investigator
Sarah Savoia
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu
1) Mental age of 4 years or greater; 2) Have a reliable study partner (caregiver, sibling, parent etc.) who can accompany participant to visits and provide information about their medical symptoms and history; 3) Must be able to speak English or Spanish fluently
1) Unable or unwilling to undergo an MRI or PET scan; 2) If Female, pregnant, plan to become pregnant in the next 16-24 months, or currently breastfeeding, 3) Also participating in a clinical trial for an investigational product.
| Arm | Description | Intervention |
|---|---|---|
Trial Ready Cohort | Non-demented adults with Down syndrome (DS) | All participants at qualifying sites will receive a single bolus intravenous injection of 5 mCi (185 MBq) (± 20%) of MK6240. At approximately 90-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed. Other names:
All participants at qualifying sites will receive a single bolus intravenous injection of 15 mCi (555 MBq) (± 10%) of PIB. At approximately 30-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed. Other names:
All participants at qualifying sites will receive a single bolus intravenous injection of 8.1 mCi (300 MBq) (+/- 20%, 10µg mass dose) of flutafuranol ([18F]NAV4694). At approximately 90-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed. Other names:
|